The India gene therapy market size is projected to exhibit a growth rate (CAGR) of 16.7% during 2024-2032. The growing awareness and acceptance of gene therapy among healthcare professionals and patients, rising prevalence of genetic disorders in India, the considerable rise in funding for gene therapy research and development (R&D) activities, and strategic collaborations between biotech firms, academic institutions, and healthcare providers represent some of the key factors driving the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Growth Rate (2024-2032) | 16.7% |
Gene therapy is a cutting-edge medical approach that holds immense promise in revolutionizing the treatment of genetic disorders and inherited diseases. It is a novel therapeutic strategy that involves the introduction, modification, or replacement of genes within a patient's cells to correct or compensate for faulty genetic information. Gene therapy is characterized by its potential for long-term and even a complete cure for certain disorders, tailored treatment procedures based on unique genetic profiles, enhanced efficacy and reduced side effects. The working mechanism of gene therapy revolves around introducing functional genes into a patient's cells to compensate for defective or non-functional genes. This can be achieved through several approaches, including gene augmentation (adding copies of functional genes), gene editing (modifying the existing genes), and gene silencing (blocking or inhibiting harmful genes). The treatment process typically begins with the isolation of healthy genes, which are then delivered into the patient's cells using various delivery mechanisms, such as viral vectors or non-viral methods. The introduced genes work alongside the patient's natural genetic material to produce necessary proteins and restore normal cellular functions.
The market in India is primarily driven by the growing awareness and acceptance of gene therapy among healthcare professionals and patients. This can be attributed to the rising prevalence of genetic disorders in India leading to an urgent need for innovative therapeutic solutions. In line with this, the considerable rise in funding for gene therapy research and development (R&D) activities by public as well as private agencies are providing a impetus to the market. Moreover, strategic collaborations between biotech firms, academic institutions, and healthcare providers expediting gene therapy advancements are creating a positive market outlook. In addition to this, the improving healthcare infrastructure and access to advanced medical facilities are resulting in a higher adoption of gene therapy in India. Besides this, the easy availability of skilled and growing workforce of geneticists, biotechnologists, and molecular biologists is advancing gene therapy research and development, which in turn is stimulating the market growth. The market is further driven by the continual advancements in gene editing technologies, such as CRISPR-Cas9 and safer gene delivery systems resulting in enhanced precision and efficacy of gene therapy interventions. Apart from this, favorable government initiatives granting orphan drug designations to gene therapies for rare diseases along with healthcare reforms and policy changes prioritizing affordable treatments for genetic diseases are fueling the market. Some of the other factors contributing to the market include rapid expansion of gene therapy clinical trials in India, streamlined and scalable manufacturing processes for gene therapies, and numerous public awareness campaigns conducted by healthcare organizations and companies.
IMARC Group provides an analysis of the key trends in each segment of the India gene therapy market report, along with forecasts at the country levels for 2024-2032. Our report has categorized the market based on gene type, vector type, delivery method, and application.
Gene Type Insights:
The report has provided a detailed breakup and analysis of the market based on the gene type. This includes antigen, cytokine, tumor suppressor, suicide gene, deficiency, growth factors, receptors, and others.
Vector Type Insights:
The report has provided a detailed breakup and analysis of the market based on the vector type. This includes viral vector (adenoviruses, lentiviruses, retroviruses, adeno-associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others) and non-viral techniques (naked and plasmid vectors, gene gun, electroporation, lipofection, and others).
Delivery Method Insights:
A detailed breakup and analysis of the market based on the delivery method has also been provided in the report. This includes in-vivo gene therapy and ex-vivo gene therapy.
Application Insights:
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and others.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include South India, North India, West & Central India, and East India.
The report has also provided a comprehensive analysis of the competitive landscape in the India gene therapy market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Units | US$ Million |
Scope of the Report | Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
|
Gene Types Covered | Antigen, Cytokine, Tumor Suppressor, Suicide Gene, Deficiency, Growth Factors, Receptors, Others |
Vector Types Covered |
|
Delivery Methods Covered | In-Vivo Gene Therapy, Ex-Vivo Gene Therapy |
Applications Covered | Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, Others |
Regions Covered | South India, North India, West & Central India, South India |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 2699 Five User License: US$ 3699 Corporate License: US$ 4699 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |